

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Medical technologies evaluation programme

Equality impact assessment: Topic selection and scoping

MTG26 Guidance update: The UroLift System for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia

The impact on equality has been assessed during this evaluation according to the principles of the [NICE Equality scheme](#).

1. Have any potential equality issues been identified during the development of the topic briefing note or during selection, and, if so, what are they?

No equality issues were identified during the development of the briefing note. It was noted that lower urinary tract symptoms secondary to benign prostatic hyperplasia are more prevalent in men of African family origin than men of white or Asian family origin.

No equality issues were identified in the original guidance, but it was noted that benign prostatic hyperplasia is associated with older patients, and that age is a protected characteristic under the 2010 Equality Act.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?

No action required.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No action required.

Approved by Associate Director: Jo Holden

Date: 17/06/20